Sep. 15 at 10:32 PM
Beta Bionics announced plans to raise
$125 million through an underwritten public offering of common stock, triggering concerns about near-term dilution after investors had reacted to several positive developments in the previous session. The offering, announced Tuesday after the close, includes a 30-day option allowing underwriters to purchase up to an additional
$18.75 million of shares.
The company said proceeds will be used for general corporate purposes, including the commercialization of its FDA-approved Mint insulin patch pump, whose full U.S. launch is now expected in the first quarter of 2027, ahead of its initial schedule. Beta Bionics also recently cut its 2026 full-year revenue outlook by about
$10 million, citing the risk that potential iLet customers could delay purchases ahead of the Mint launch. An insider sale of roughly 37,000 shares earlier in the week added to investor concerns.
$BBNX